methamphetamine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1732 537-46-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • methamphetamine
  • (S)-Methamphetamine
  • methylamphetamine
  • D-Methylamphetamine
  • methamphetamine hydrochloride
  • metamfetamine
  • methamphetamine HCl
A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.
  • Molecular weight: 149.24
  • Formula: C10H15N
  • CLOGP: 1.89
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 12.03
  • ALOGS: -2.21
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 0 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1000 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 40 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.92 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 67 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 4.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.85 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 12 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1943 FDA RECORDATI RARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 2994.92 49.07 698 2534 64828 53281006
Toxicity to various agents 1059.33 49.07 417 2815 219181 53126653
Completed suicide 426.35 49.07 193 3039 138008 53207826
Cardio-respiratory arrest 202.19 49.07 89 3143 58669 53287165
Death 197.14 49.07 166 3066 357066 52988768
Respiratory arrest 184.09 49.07 71 3161 33469 53312365
Cardiac arrest 168.33 49.07 91 3141 93576 53252258
Intentional product misuse 102.72 49.07 53 3179 49339 53296495
Poisoning 78.27 49.07 30 3202 13820 53332014
Substance abuse 70.60 49.07 21 3211 4473 53341361
Drug screen positive 64.78 49.07 19 3213 3853 53341981
Overdose 52.57 49.07 47 3185 107689 53238145

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 3758.03 50.78 1066 4201 79177 32429082
Toxicity to various agents 1573.11 50.78 690 4577 177351 32330908
Completed suicide 323.44 50.78 195 5072 92322 32415937
Respiratory arrest 288.31 50.78 124 5143 28784 32479475
Cardio-respiratory arrest 253.85 50.78 140 5127 55849 32452410
Cardiac arrest 194.84 50.78 145 5122 96631 32411628
Drug abuser 144.67 50.78 45 5222 4139 32504120
Overdose 130.91 50.78 110 5157 86967 32421292
Intentional product misuse 107.61 50.78 69 5198 35982 32472277
Death 106.68 50.78 207 5060 382310 32125949
Poisoning 104.88 50.78 46 5221 11112 32497147
Incorrect route of product administration 83.93 50.78 40 5227 11686 32496573
Accidental overdose 83.60 50.78 47 5220 19292 32488967
Drug screen positive 76.57 50.78 28 5239 4213 32504046
Substance abuse 69.04 50.78 30 5237 7077 32501182
Brain oedema 60.10 50.78 33 5234 12927 32495332
Amphetamines positive 54.87 50.78 11 5256 160 32508099

Pharmacologic Action:

SourceCodeDescription
ATC N06BA03 NERVOUS SYSTEM
PSYCHOANALEPTICS
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Centrally acting sympathomimetics
FDA CS M0001015 Amphetamines
FDA PE N0000175372 Appetite Suppression
FDA EPC N0000175425 Amphetamine Anorectic
MeSH PA D018663 Adrenergic Agents
MeSH PA D018759 Adrenergic Uptake Inhibitors
MeSH PA D002491 Central Nervous System Agents
MeSH PA D000697 Central Nervous System Stimulants
MeSH PA D015259 Dopamine Agents
MeSH PA D018765 Dopamine Uptake Inhibitors
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D013566 Sympathomimetics
CHEBI has role CHEBI:35337 analeptic drug
CHEBI has role CHEBI:35471 psychopharmaceuticals
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:50910 agente neurotoxico
CHEBI has role CHEBI:78298 environmental contaminants
FDA PE N0000175651 Increased Sympathetic Activity
FDA PE N0000175729 Central Nervous System Stimulation
FDA EPC N0000175739 Central Nervous System Stimulant

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Attention deficit hyperactivity disorder indication 406506008
Obesity indication 414916001 DOID:9970
Gilles de la Tourette's syndrome contraindication 5158005 DOID:11119
Suicidal thoughts contraindication 6471006
Dependent drug abuse contraindication 6525002
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Bipolar disorder contraindication 13746004 DOID:3312
Hepatic encephalopathy contraindication 13920009 DOID:13413
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Feeling agitated contraindication 24199005
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Hyperactive behavior contraindication 44548000
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Anorexia nervosa contraindication 56882008 DOID:8689
Hepatic failure contraindication 59927004
Aggressive behavior contraindication 61372001
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Arteriosclerotic vascular disease contraindication 72092001
Hepatic coma contraindication 72836002 DOID:12550
Sleep apnea contraindication 73430006 DOID:0050847
Cardiomyopathy contraindication 85898001 DOID:0050700
Weight loss contraindication 89362005
Kidney disease contraindication 90708001 DOID:557
Structural disorder of heart contraindication 128599005
Seizure disorder contraindication 128613002
Motor tic disorder contraindication 230337001
Cerebrovascular accident contraindication 230690007
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Sleep automatism contraindication 247962006
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Cardiovascular event risk contraindication 395112001
Visual impairment contraindication 397540003
Respiratory insufficiency contraindication 409623005
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Porphyria contraindication 418470004
Hypertensive urgency contraindication 443482000
Acute exacerbation of asthma contraindication 708038006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.73 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent dopamine transporter Transporter INHIBITOR Ki 7.61 PDSP CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 5.38 PDSP
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 5.08 CHEMBL
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 6.13 PDSP
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 7.91 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 5 PDSP
Alpha-2B adrenergic receptor GPCR Ki 6.13 PDSP
Alpha-2C adrenergic receptor GPCR Ki 6.09 PDSP
Trace amine-associated receptor 1 GPCR AGONIST EC50 5.89 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 6.88 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 7.15 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 5.28 CHEMBL
Synaptic vesicular amine transporter Transporter Ki 5.61 CHEMBL

External reference:

IDSource
4019821 VUID
N0000147910 NUI
D02242 KEGG_DRUG
51-57-0 SECONDARY_CAS_RN
4018483 VANDF
4019821 VANDF
C0025611 UMLSCUI
CHEBI:6809 CHEBI
B40 PDB_CHEM_ID
CHEMBL1201201 ChEMBL_ID
DB01577 DRUGBANK_ID
CHEMBL1200952 ChEMBL_ID
D008694 MESH_DESCRIPTOR_UI
10836 PUBCHEM_CID
1879 INN_ID
4803 IUPHAR_LIGAND_ID
44RAL3456C UNII
6816 RXNORM
1988 MMSL
5066 MMSL
d00805 MMSL
001797 NDDF
004722 NDDF
387329009 SNOMEDCT_US
387499002 SNOMEDCT_US
8692006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Methamphetamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-0389 TABLET 5 mg ORAL ANDA 25 sections
Desoxyn HUMAN PRESCRIPTION DRUG LABEL 1 55292-102 TABLET 5 mg ORAL NDA 25 sections
Desoxyn HUMAN PRESCRIPTION DRUG LABEL 1 55292-104 TABLET 5 mg ORAL NDA 25 sections
Methamphetamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68308-115 TABLET 5 mg ORAL ANDA 29 sections